(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 53.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.19%.
Axsome Therapeutics's revenue in 2024 is $291,489,000.On average, 7 Wall Street analysts forecast AXSM's revenue for 2024 to be $17,943,916,635, with the lowest AXSM revenue forecast at $17,251,273,677, and the highest AXSM revenue forecast at $18,782,480,217. On average, 7 Wall Street analysts forecast AXSM's revenue for 2025 to be $30,522,322,355, with the lowest AXSM revenue forecast at $22,548,576,301, and the highest AXSM revenue forecast at $35,431,063,320.
In 2026, AXSM is forecast to generate $52,253,743,166 in revenue, with the lowest revenue forecast at $44,491,390,015 and the highest revenue forecast at $63,026,669,175.